Methods and results
- The first clinical report of long-term outcome of CD34+ cell therapy in CLI.
- High CLI-free ratio was sustained for 4 years post CD34+ cell therapy.
- Significant improvement of TBPI and TcPO2 was sustained for 3–4 years.
- Favorable outcomes indicate long-term benefit of the cell therapy for CLI patients.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) endorsed by the American association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; transatlantic inter-society consensus; and vascular disease foundation.J Am Coll Cardiol. 2006; 47: 1239-1312
- Inter-society consensus for the management of peripheral arterial disease (TASC II).J Vasc Surg. 2007; 45: S5-67
- Isolation of putative progenitor endothelial cells for angiogenesis.Science. 1997; 275: 964-967
- Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization.Proc Natl Acad Sci U S A. 2000; 97: 3422-3427
- Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia.Circulation. 2001; 103: 634-637
- Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model.J Clin Invest. 2004; 114: 330-338
- Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial.Lancet. 2002; 360: 427-435
- Critical roles of muscle-secreted angiogenic factors in therapeutic neovascularization.Circ Res. 2006; 98: 1194-1202
- Bone marrow mononuclear cells versus G-CSF-mobilized peripheral blood mononuclear cells for treatment of lower limb ASO: pooled analysis for long-term prognosis.Bone Marrow Transplant. 2011; 46: 278-284
- Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial.Stem Cells. 2009; 27: 2857-2864
- Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia.Bone Marrow Transplant. 2010; 45: 111-116
- Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (therapeutic angiogenesis by cell transplantation [TACT] trial) in patients with chronic limb ischemia.Am Heart J. 2008; 156: 1010-1018
- Long-term outcome of therapeutic neovascularization using peripheral blood mononuclear cells for limb ischemia.Circ Cardiovasc Interv. 2009; 2: 245-254
- Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells.Atherosclerosis. 2010; 208: 461-466
- Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: a comparison of atherosclerotic peripheral arterial disease and Buerger disease.Circ Cardiovasc Interv. 2011; 4: 15-25
- Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans.Circulation. 2006; 114: 2679-2684
- Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease.Circ Res. 2001; 89: E1-E7
- Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures.Circulation. 2002; 106: 2781-2786
- Molecular evaluation of endothelial progenitor cells in patients with ischemic limbs: therapeutic effect by stem cell transplantation.Arterioscler Thromb Vasc Biol. 2004; 24: e192-e196
- Intramyocardial, autologous CD34+ cell therapy for refractory angina.Circ Res. 2011; 109: 428-436
- Local delivery of granulocyte colony stimulating factor-mobilized CD34-positive progenitor cells using bioscaffold for modality of unhealing bone fracture.Stem Cells. 2008; 26: 1395-1405
- Human peripheral blood CD34-positive cells enhance therapeutic regeneration of chronically injured liver in nude rats.J Cell Physiol. 2012; 227: 1538-1552
- Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes.Diabetes Care. 2005; 28: 2155-2160
- Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer.Cell Transplant. 2010; 19: 1413-1424
- Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA).Circ Cardiovasc Interv. 2011; 4: 26-37
- The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: implications for clinical trial design.J Transl Med. 2011; 9: 165
- Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia.J Vasc Surg. 2011; 54: 1650-1658